Cerion’s subsidiary Cerion NRX published a research study in the American Chemical Society’s ACS Nano journal for its new breakthrough experimental therapy to treat neurodegenerative diseases such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis. In the published study, the compound was well tolerated upon administration to mice and was able to penetrate the brain while significantly alleviating clinical symptoms and motor deficits associated with a murine model of multiple sclerosis.

To read the full journal article, click here.

For Press Inquiries
Brad Stadler, Ph.D.
Executive Vice President, Biologics
Telephone: +1.585.271.5630 ext. 126
E.mail: brad.stadler@cerionam.com